Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort
- PMID: 32024593
- DOI: 10.1016/j.semarthrit.2019.12.001
Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort
Abstract
Background: In 2017, the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) published new classification criteria for idiopathic inflammatory myopathies (IIM).
Objectives: To [1] assess the performance of the EULAR/ACR criteria in a monocentric cohort of consecutive patients with IIM, compare them with the Bohan and Peter (BP) criteria, and with the physician's diagnosis; and [2] evaluate the effect of including the presence of interstitial lung disease (ILD) as variable in the criteria.
Methods: 439 consecutive patients with a diagnosis of IIM followed at the Rheumatology Clinic, Karolinska University Hospital, Sweden were enrolled. The patients were diagnosed as IIM and subclassified by expert physicians. Clinical, laboratory, serological and histopathological data were collected from existing databases (Euromyositis registry and Swedish Rheumatology quality registry) and clinical charts of the patients. The sensitivity of the EULAR/ACR and the BP criteria was calculated.
Results: The EULAR/ACR criteria had a higher sensitivity (87.7%) compared to the BP criteria (80.4%). The concordance between the two sets of criteria was low (k = 0.253 p<0.001). The EULAR/ACR criteria showed a very high specificity (>98%) for the major IIM subgroups polymyositis, dermatomyositis, and inclusion body myositis. The sensitivity was variable and was high in inclusion body myositis (98%), dermatomyositis (90%) and lower in polymyositis (73%). When including ILD in the variables of the criteria, six more patients were classified as IIM cases (1.3%).
Conclusion: The EULAR/ACR criteria for IIM are applicable with high sensitivity and specificity using data available from existing databases and clinical charts and represent a major step forward from the previous criteria for IIM and its subgroups. Their application will improve the quality of clinical trials and research studies with IIM patients.
Keywords: Classification; Criteria; Dermatomyositis; Idiopathic inflammatory myopathies; Myositis; Polymyositis.
Copyright © 2019. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest The authors have no competing interest to declare.
Similar articles
-
Performance of the 2017 EULAR/ACR criteria for idiopathic inflammatory myopathies in a cohort of patients from Latin America.Medicine (Baltimore). 2022 Oct 28;101(43):e31015. doi: 10.1097/MD.0000000000031015. Medicine (Baltimore). 2022. PMID: 36316860 Free PMC article.
-
The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort.Rheumatology (Oxford). 2019 Mar 1;58(3):468-475. doi: 10.1093/rheumatology/key343. Rheumatology (Oxford). 2019. PMID: 30496561 Free PMC article.
-
First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort.Ann Rheum Dis. 2020 Mar;79(3):387-392. doi: 10.1136/annrheumdis-2019-215488. Epub 2019 Nov 6. Ann Rheum Dis. 2020. PMID: 31694813
-
New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter.Curr Rheumatol Rep. 2018 Mar 17;20(4):18. doi: 10.1007/s11926-018-0726-4. Curr Rheumatol Rep. 2018. PMID: 29550929 Free PMC article. Review.
-
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.Ann Rheum Dis. 2017 Dec;76(12):1955-1964. doi: 10.1136/annrheumdis-2017-211468. Epub 2017 Oct 27. Ann Rheum Dis. 2017. PMID: 29079590 Free PMC article.
Cited by
-
Dermatomyositis: Practical Guidance and Unmet Needs.Immunotargets Ther. 2024 Mar 6;13:151-172. doi: 10.2147/ITT.S381472. eCollection 2024. Immunotargets Ther. 2024. PMID: 38464459 Free PMC article. Review.
-
Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.Front Immunol. 2023 Nov 27;14:1237209. doi: 10.3389/fimmu.2023.1237209. eCollection 2023. Front Immunol. 2023. PMID: 38098481 Free PMC article.
-
Deciphering the crosstalk of immune dysregulation between COVID-19 and idiopathic inflammatory myopathy.Front Immunol. 2023 Aug 10;14:1197493. doi: 10.3389/fimmu.2023.1197493. eCollection 2023. Front Immunol. 2023. PMID: 37638007 Free PMC article.
-
Clinical Characteristics and Associated Factors for Infection and in-Hospital Mortality in Inpatients with Polymyositis/Dermatomyositis in China: A Retrospective Study.Infect Drug Resist. 2023 Jan 17;16:289-299. doi: 10.2147/IDR.S392585. eCollection 2023. Infect Drug Resist. 2023. PMID: 36691492 Free PMC article.
-
Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up.J Transl Autoimmun. 2022 Feb 11;5:100148. doi: 10.1016/j.jtauto.2022.100148. eCollection 2022. J Transl Autoimmun. 2022. PMID: 35243286 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
